Warhound Secures $200 Million Seed Round Valued at $1.2 Billion, Plans to Produce Healthier Military Working Dogs Through Cloning and Gene Editing
Warhound emerged from stealth on October 22, 2026, completing a $200 million seed round financing, with a valuation of $1.2 billion. The company was co-conceived by Palmer Luckey, founder of Anduril, and Ben Lamm, co-founder of Colossal Biosciences.
The company plans to produce healthier military working dogs through cloning and gene editing, reducing reliance on imported dogs from Europe. Over 80% of military working dogs in the U.S. come from Europe, with a qualification rate of less than half after training. The target breeds are primarily Belgian Malinois, supplemented by some Labradors and Shepherds.
Anduril will provide external equipment for the dogs, including goggles, hearing protection, bulletproof vests, and integration with the EagleEye system, enhancing situational awareness for both the dogs and their handlers. The initial focus of gene editing will be on reducing genetic issues such as hip dysplasia and muscle atrophy, with potential future introduction of scent-related genes.
The CEO is David Spirk, a former Marine and former Chief Data Officer at the Pentagon. Investors include Sequoia, In-Q-Tel, and ARK Invest. Luckey himself does not hold equity, and Anduril has no stake; Colossal provides technology licensing and holds economic rights.
The company has collected cell samples from excellent working dogs and begun editing, with the first batch of cloned dogs expected to be born in early 2027. The American Humane Association will certify its training program.
Market dynamics show that the demand for reliable working dogs from defense and law enforcement sectors is driving funding into the vertical field of biotechnology and equipment integration. Reducing import reliance benefits the domestic supply chain, while traditional European breeders may face declining demand. Capital is concentrated on platforms capable of cloning and gene editing.
Source: Public Information
ABAB AI Insight
Palmer Luckey founded Anduril, focusing on AI-driven defense systems. Ben Lamm promotes de-extinction and gene editing projects through Colossal Biosciences, including work related to wolves. The two discussed the issue of working dogs at a meeting around 2025, leading to the launch of Warhound in October 2026.
In terms of capital, the $200 million seed round was led by Sequoia, with In-Q-Tel's participation indicating interest in intelligence and defense. The funds will be used for biobanking, cloning, gene editing, and integration with Anduril equipment. Luckey does not hold shares, reducing conflicts of interest, while Colossal shares profits through technology licensing.
This is similar to other attempts to integrate biotechnology into the defense supply chain, or Colossal's cloning applications in other species. Currently, the supply of working dogs relies on imports and has a low qualification rate; the company aims to replace traditional breeding with genetic screening.
Essentially, this is a restructuring of the industrial chain. By reducing genetic defects through gene editing and cloning, and enhancing usability with external equipment, it changes the reliance on European breeders. The mechanism lies in technology reducing training elimination rates, making domestic supply a viable alternative.
ABAB News · Cognitive Law
Working dogs rely on imports; gene editing aims to raise them domestically.
Equipment is external, genes are internal; each manages its own.
Founders without equity can still push concepts forward.